Ind-Swift Laboratories Limited Share Price Bombay S.E.
Equities
INDSWFTLAB
INE915B01019
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
115.9 INR | -6.00% | -7.11% | +11.52% |
19/04 | Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai | MT |
19/04 | Ind-Swift Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary | CI |
Sales 2022 | 10.52B 126M | Sales 2023 | 12.16B 146M | Capitalization | 3.26B 39.09M |
---|---|---|---|---|---|
Net income 2022 | -21M -252K | Net income 2023 | 476M 5.71M | EV / Sales 2022 | 1.26 x |
Net Debt 2022 | 9.32B 112M | Net Debt 2023 | 8.44B 101M | EV / Sales 2023 | 0.96 x |
P/E ratio 2022 |
-183
x | P/E ratio 2023 |
6.85
x | Employees | 1,496 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.86% |
1 day | -6.00% | ||
1 week | -7.11% | ||
Current month | -3.09% | ||
1 month | +4.13% | ||
3 months | +6.97% | ||
6 months | +30.84% | ||
Current year | +11.52% |
Managers | Title | Age | Since |
---|---|---|---|
Navrattan Munjal
CEO | Chief Executive Officer | 72 | 04/95/04 |
Himanshu Jain
CEO | Chief Executive Officer | 41 | - |
Gagan Aggarwal
DFI | Director of Finance/CFO | - | 29/18/29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Himanshu Jain
CEO | Chief Executive Officer | 41 | - |
Navrattan Munjal
CEO | Chief Executive Officer | 72 | 04/95/04 |
Director/Board Member | 68 | 31/09/31 |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 115.9 | -6.00% | 25,089 |
02/24/02 | 123.3 | +3.10% | 45,754 |
30/24/30 | 119.6 | -1.83% | 23,783 |
29/24/29 | 121.8 | -2.36% | 28,537 |
26/24/26 | 124.8 | +0.29% | 48,759 |
Delayed Quote Bombay S.E., May 03, 2024 at 03:30 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+19.98% | 43.48B | |
+20.67% | 22.65B | |
+14.56% | 14.73B | |
+44.72% | 12.04B | |
-8.37% | 7.08B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+11.90% | 5.47B | |
-2.27% | 4.81B |
- Stock Market
- Equities
- INDSWFTLAB Stock
- INDSWFTLAB Stock